• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Isobutyl iodide
4-Bromo-1-butene
Paradol
Oligopeptide - 1
Acalabrutinib 1420477-60-6 High Quality and Competitive Price for API
High Quality Unii-4u07f515LG / Eltrombopag Olamine / CAS 496775-62-3

29 monoclonal antibody drugs marketed in China

XiaoyaowanNovember 13, 2018

Tag: china , Generic , Monoclonal Antibody Drugs

China’s monoclonal antibody market is far behind the European and American developed countries no matter in terms of sales scale or product quantity and variety; compared to global market, size of China’s monoclonal antibody market is still small, and is estimated to account for about 1% of global monoclonal antibody market. FDA approved a total of 77 monoclonal antibody drugs by the end of 2017, including 7 monoclonal antibody biosimilars, while the number of monoclonal antibody drugs approved for marketing in China has reached 29, including 19 imported monoclonal antibody drugs and 10 Chinese-produced monoclonal antibody drugs.

Generic name

Trade name

Manufacturer

Marketing time in China

Rituximab

Rituxan

Roche

2000

Trastuzumab

Herceptin

Roche

2002

Basiliximab

Simulect

Novartis

2003

Cetuximab

Erbitux

Merck

2005

Infliximab

Remicade

J & J

2007

Bevacizumab

Avastin

Roche

2010

Adalimumab

Humira

AbbVie

2010

Etanercept

Enbrel

Pfizer

2010

Ranibizumab

Lucentis

Novartis

2011

Tocilizumab

Actemra

Roche

2013

Omalizumab

Xolair

Roche

2017

Ustekinumab

Stelara

J & J

2017

Golimumab

Simponi

J & J

2018

Aflibercept

Eylea

Bayer

2018

Idarucizumab

Praxbind

Boehringer Ingelheim

2018

Nivolumab

Opdivo

BMS

2018

Pembrolizumab

Keytruda

Merck

2018

Evolocumab

Repatha

Amgen

2018

Eculizumab

Soliris

Alexion

2018

Recombinant human tumor necrosis factor receptor type II-IgG Fc fusion

Yisaipu

CP Guojian Pharm

2006

Iodine[131I] tumor necrosis human/mouse chimeric monoclonal antibody

Vivatuxin

MediPharm Biotech

2007

Nimotuzumab

Taixinsheng

Biotech Pharma

2008

Muromomab

/

Wuhan Institute of Biological Products

2010

Anti-human IL-8 monoclonal antibody

Abcream

Asia Space Pharmaceutical [Dalian]

2010

Recombinant human tumor necrosis factor receptor type II-IgG Fc fusion

Qiangke

Celgen Biopharma

2011

Dalizumab

Jiannipai

CP Guojian Pharm

2011

Iodine[131I] metuximab

Likating

Huasun Biotechnology

2011

Conbercept

Langmu

Kanghong Pharmaceutical

2013

Recombinant human tumor necrosis factor-α receptor II:IgG Fc fusion

Anbainuo

Hisun Pharmaceutical

2015
 
Read More:
 
 

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

 

Previous:Amazing Monthly Sales Performance of Opdivo and Keytruda in China

Next:Monoclonal antibody drugs in development in China

Related News

Olympus Launches New 4K Camera Head for Urological Endoscopy

PharmaSourcesSeptember 24, 2024

Unified Visualization with True 4K Imaging and 4K Narrow Band Imaging as well as blue light observation

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

29 monoclonal antibody drugs marketed in China | Pharmasources.com

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the European Society for Medical Oncology (ESMO) Congress 2024.

You may like
More>>

Echinacea Angustifolia Extract Powder 4%HPLC

Echinacea Angustifolia Extract Powder 4%HPLC
Tylosin Tartrate veterinary pharmaceutical BPV China supplier

Tylosin Tartrate veterinary pharmaceutical BPV China supplier
Fosinopril 98.0%min Pharmaceutical Anti hypertensive drugs Cardiovascular drugs made in china

Fosinopril 98.0%min Pharmaceutical Anti hypertensive drugs Cardiovascular drugs made in china
Pramlintide acetate supplier API Pharmaceutical Polypeptide made in china

Pramlintide acetate supplier API Pharmaceutical Polypeptide made in china
Esmolol hydrochloride 99%min Pharmaceutical Cardiovascular diseases made in china

Esmolol hydrochloride 99%min Pharmaceutical Cardiovascular diseases made in china
Hydroxocobalamin EP API Vitamins made in china

Hydroxocobalamin EP API Vitamins made in china
China Flu Shots-Hualan Bio

China Flu Shots-Hualan Bio
Sulfamide USP supplier API Pharmaceutical Sulfanilamide made in china

Sulfamide USP supplier API Pharmaceutical Sulfanilamide made in china
Neocuproine hemihydrate ≥98.0% API Biological made in china

Neocuproine hemihydrate ≥98.0% API Biological made in china
4,6-Dimethyl-2-methylsulfonylpyrimidine Intermediate Pyrimidine made in china

4,6-Dimethyl-2-methylsulfonylpyrimidine Intermediate Pyrimidine made in china

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service